IP Library Granted Patent US 9,771,576
Granted Patent B2
US 9,771,576 · App. 13/757,633 · Granted Sep 26, 2017

Materials and methods for the synthesis of error-minimized nucleic acid molecules

Inventors: Daniel G. Gibson (Carlsbad, CA); Nicky Caiazza (Rancho Sana Fe, CA); Toby H. Richardson (San Diego, CA)
Assignee: Synthetic Genomics, Inc.
C12N15/1093C12N9/22C12P19/34C12Q1/6844C12Y301/11C12Y301/21C07K2319/00C07K2319/036C07K2319/21
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,771,576
App. No.
13/757,633
Granted
Sep 26, 2017
Kind
B2
Abstract

The present invention provides materials and methods useful for error correction of nucleic acid molecules. In one embodiment of the invention, a first plurality of double-stranded nucleic acid molecules having a nucleotide mismatch are fragmented by exposure to a molecule having unidirectional mismatch endonuclease activity. The nucleic acid molecules are cut at the mismatch site or near the mismatch site, leaving a double-stranded nucleic acid molecule having a mismatch at the end or near end of the molecule. The nucleic acid molecule is then exposed to a molecule having unidirectional exonuclease activity to remove the mismatched nucleotide. The missing nucleotides can then be filled in by the action of, e.g., a molecule having DNA polymerase activity. The result is double-stranded nucleic acid molecules with a decreased frequency of nucleotide mismatches. Also provided are novel nucleic acid sequences encoding mismatch endonucleases, polypeptides encoded thereby, as well as nucleic acid constructs, transgenic cells, and various compositions thereof.

Claims (32)

1. A method for error correction of nucleic acid molecules, said method comprising:

(a) amplifying double-stranded nucleic acid molecules of a desired sequence;

(b) obtaining a first plurality of amplified double-stranded nucleic acid molecules comprising a) nucleic acid molecules of the desired sequence and b) nucleic acid molecules having at least one nucleotide mismatch relative to the desired sequence;

(c) fragmenting said first plurality of amplified double-stranded nucleic acid molecules by reacting said nucleic acid molecules with at least one molecule having unidirectional mismatch endonuclease activity;

(d) removing said at least one nucleotide mismatch by reacting said fragmented double-stranded nucleic acid molecules of (c) with at least one molecule having unidirectional exonuclease activity of the same directionality as the unidirectional mismatch endonuclease activity of (c) to provide a fragmented error-free double-stranded nucleic acid molecule of the desired sequence; and

(e) assembling a second plurality of double-stranded nucleic acid molecules comprising said fragmented error-free double-stranded nucleic acid molecule of (d), wherein the second plurality of double-stranded nucleic acid molecules has a higher proportion of nucleic acid molecules having the desired sequence and a decreased frequency of nucleotide mismatches compared to said first plurality of double-stranded nucleic acid molecules; and

wherein steps (a)-(e) are carried out in sequential order as listed.

2. A method according to claim 1 , wherein said first plurality of nucleotide acid molecules comprises one or more synthetic nucleotide sequences.

3. A method according to claim 1 , wherein said first plurality of nucleotide acid molecules comprises a mixture of one or more naturally occurring gene sequences and one or more synthetic nucleotide sequences.

4. A method according to claim 1 , wherein obtaining a first plurality of nucleic acid molecules comprises synthesizing the nucleic acid molecules.

5. A method according to claim 1 , wherein obtaining a first plurality of nucleic acid molecules comprises assembling the nucleic acid molecules from subsets and/or oligonucleotides.

6. A method according to claim 1 , wherein step (c) and step (d) are performed as separate reactions.

7. A method according to claim 1 , wherein step (c) and step (d) are performed as a one-step, simultaneous reaction.

8. A method according to claim 1 , wherein said unidirectional mismatch endonuclease activity cuts 5′ to said mismatch and said unidirectional exonuclease activity removes said nucleotide mismatch from the 5′ end of said fragmented nucleic acid molecule.

9. A method according to claim 1 , wherein said unidirectional mismatch endonuclease activity cuts 3′ to said mismatch and said unidirectional exonuclease activity removes said nucleotide mismatch from the 3′ end of said fragmented nucleic acid molecule.

10. A method according to claim 1 , wherein said at least one molecule having unidirectional mismatch endonuclease activity is selected from the group consisting of RES I, CEL I, CEL II, an SP endonuclease, SP I, T7 endonuclease, T4 endonuclease, endonuclease V, a Mut protein, a variant of any thereof, and a combination of any two or more of the above.

11. A method according to claim 10 , wherein, said at least one molecule having unidirectional mismatch endonuclease activity is selected from the group consisting of: CEL I, CEL II, a variant of any thereof, and a combination of any two or more of the above.

12. A method according to claim 1 , wherein said at least one molecule having unidirectional exonuclease activity is selected from the group consisting, of exonuclease III, a DNA polymerase, lambda exonuclease, T7 exonuclease, T5 exonuclease, and a variant of, any thereof.

13. A method according to claim 1 , wherein said at least one molecule having unidirectional exonuclease activity is a polymerase with proofreading activity.

14. A method according to claim 13 , wherein said polymerase with proofreading activity is selected from the group consisting of T4 polymerase, T7 polymerase, and phi29 polymerase.

15. A method according to claim 1 , wherein said at least one molecule having unidirectional mismatch endonuclease activity is selected from the group consisting of CEL I, CEL II, a variant of any thereof, and a combination of any two or more of the above; and said at least one molecule having unidirectional exonuclease activity is selected from the group consisting of exonuclease III and a variant thereof.

16. The method according to claim 1 wherein the at least one molecule having unidirectional mismatch endonuclease activity is encoded by a nucleic acid sequence selected from the group consisting of:

(a) a nucleic acid sequence exhibiting 90% or greater identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO: 09, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30-33, a complement of any, and a fragment of any; and

(b) a nucleic acid sequence encoding a polypeptide exhibiting 90% or greater identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 29.

17. The method of claim 1 , wherein the molecule having unidirectional exonuclease activity is exonuclease III.

18. The method of claim 1 , wherein the molecule having unidirectional mismatch endonuclease activity is CEL I or CEL II, and the molecule having unidirectional exonuclease activity is exonuclease III.

19. The method of claim 1 , wherein the molecule having unidirectional mismatch endonuclease activity exhibits 90% or greater identity to SEQ ID NO: 10 or SEQ ID NO: 16.

20. The method of claim 19 , wherein the molecule having unidirectional exonuclease activity is exonuclease III.

21. The method of claim 19 , wherein the molecule having unidirectional mismatch endonuclease activity is SEQ ID NO: 10.

22. The method of claim 21 , wherein the molecule having unidirectional exonuclease activity is exonuclease III.

23. The method of claim 19 , wherein the molecule having unidirectional mismatch endonuclease activity is SEQ ID NO: 16.

24. The method of claim 23 , wherein the molecule having unidirectional exonuclease activity is exonuclease III.

Assignments (9)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (TERM) Recorded Jul 16, 2024
From: MIDCAP FINANCIAL TRUST
To: TELESIS BIO INC. (FORMERLY KNOWN AS CODEX DNA, INC.); ETONBIO, INC.
Reel/Frame 068390/0070 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (REVOLVING) Recorded Jul 16, 2024
From: MIDCAP FUNDING IV TRUST
To: TELESIS BIO INC. (FORMERLY KNOWN AS CODEX DNA, INC.); ETONBIO, INC.
Reel/Frame 068390/0001 →
CHANGE OF NAME Recorded Apr 19, 2023
From: CODEX DNA, INC.
To: TELESIS BIO INC.
Reel/Frame 063379/0581 →
SECURITY INTEREST (REVOLVING) Recorded Aug 18, 2022
From: CODEX DNA, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 061208/0063 →
SECURITY INTEREST (TERM) Recorded Aug 18, 2022
From: CODEX DNA, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061208/0080 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2020
From: OXFORD FINANCE LLC
To: SYNTHETIC GENOMICS, INC.; GENOVIA BIO, LLC; GREEN RESOURCES, LLC; SGI-DNA, INC.; SYNTHETIC GENOMICS VACCINES, INC.
Reel/Frame 054372/0822 →
CHANGE OF NAME Recorded May 19, 2020
From: SGI-DNA, INC.
To: CODEX DNA, INC.
Reel/Frame 052705/0893 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2019
From: SYNTHETIC GENOMICS, INC.
To: SGI-DNA, INC.
Reel/Frame 049602/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2013
From: GIBSON, DANIEL G.; CAIAZZA, NICKY C.; RICHARDSON, TOBY H.
To: SYNTHETIC GENOMICS, INC.
Reel/Frame 030131/0414 →
Continuity (2)
Provisional Application 61593813 · Feb 1, 2012
Related Publication 20130225451A1 · Aug 29, 2013